drugset / Trial / NCT04041674
Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants
Phase 1
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
Duke University · collabGeoVax Labs, Inc · collabHIV Vaccine Trials Network (HVTN), Fred Hutch / University of Washington · collabUniversity of Maryland, Baltimore · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of GEO-D02 DNA and MVA/HIV62B with and without B63521\^11 gp120 and IHV01 gp120 Env proteins in healthy, HIV-uninfected adult participants.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2022-09-30
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B63521^11 gp120 | Protein / enzyme biologic | 150 ug | Intramuscular |
| Subject | GEO-D02 | Vaccine | 3 mg | Intramuscular |
| Subject | IHV01 | Vaccine | 150 ug | Intramuscular |
| Subject | MVA/HIV62B | Vaccine | 1e+08 unknown | Intramuscular |